MTP - Midatech Pharma Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7701
-0.1812 (-19.05%)
At close: 3:58PM EDT

0.8400 +0.07 (9.08%)
After hours: 4:55PM EDT

Stock chart is not supported by your current browser
Previous Close0.9513
Open0.9500
Bid0.7700 x 4000
Ask0.8888 x 1200
Day's Range0.7700 - 0.9500
52 Week Range0.6610 - 3.2700
Volume386,193
Avg. Volume156,288
Market Cap25.766M
Beta0.40
PE Ratio (TTM)N/A
EPS (TTM)-1.3400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE19 days ago

    Today’s Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / There was no catalyst or news to send shares of both Midatech and Eleven Biotherapeutics higher on Wednesday. Midatech Pharma Plc shares closed up 10.56% yesterday with more gains seen in after-hours trading as well. There was no significant news from the specialty pharmaceutical company to explain the move up.

  • Zacks Small Cap Research25 days ago

    MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201

    Midatech Pharma Plc (MTP) is a specialty pharmaceutical company with three novel drug delivery technologies. The technologies are designed to enable the targeted delivery, sustained release, or solubilized local delivery of existing therapeutic drugs. The gold nanoparticle (GNP) technology platform is based on GNP drug conjugates, which at 2 nm are among the smallest particles in biomedical use.

  • Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry
    Simply Wall St.2 months ago

    Where Münchener Tierpark Hellabrunn AG’s (MUN:MTP) Earnings Growth Stands Against Its Industry

    Examining how Münchener Tierpark Hellabrunn AG (MUN:MTP) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple senseRead More...

  • GlobeNewswire2 months ago

    Midatech announces changes in Senior Management Team

    15 March 2018 Midatech Pharma PLC. Midatech announces changes in Senior Management Team. Midatech, the international specialty pharmaceutical company focused on developing and commercialising products ...

  • Zacks Small Cap Research2 months ago

    MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017

    On January 16, 2018, Midatech Pharma Plc (MTP) announced that the U.S. Food and Drug Administration (FDA) approved the investigational new drug (IND) application to initiate a clinical trial of MTX110 in patients with diffuse intrinsic pontine glioma (DIPG). The active compound in MTX110 is the poorly soluble hydroxamic acid drug panobinostat, a histone deacetylase inhibitor (HDACi), which until recently could not be formulated for parenteral administration.

  • GlobeNewswire3 months ago

    Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency

    28 February 2018 Midatech Pharma PLC. Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency. Midatech, the international specialty pharmaceutical company focused on developing ...

  • Zacks Small Cap Research4 months ago

    MTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap Financial

    On January 9, 2018, Midatech Pharma Plc (MTP) announced that Polish regulators have given approval to initiate the company’s first in-human clinical trial of Q-Octreotide (MTD201). Q-Octreotide is the sustained release (SR) version of octreotide, an octapeptide that mimics naturally occurring somatostatin. Octreotide is an existing, immediate- and sustained- release injection product used to decrease the production of growth hormone in people suffering from acromegaly and for the treatment of neuroendocrine (hormone secreting) tumors (NET).

  • Zacks Small Cap Research6 months ago

    Initiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic Areas

    We are initiating coverage of Midatech Pharma Plc (NASDAQ:PLC) with a $6.00 valuation. MIdatech is a U.K. based international specialty pharmaceutical company focused on oncology and other therapeutic areas. The company has three proprietary drug delivery technologies: Q-Sphera for sustained release of already marketed products, Midacore gold nanoparticles (GNP) for targeted delivery, and Nano Inclusion (NI) for local delivery.

  • Is Midatech Pharma Plc (AIM:MTPH) Undervalued?
    Simply Wall St.7 months ago

    Is Midatech Pharma Plc (AIM:MTPH) Undervalued?

    Midatech Pharma Plc (AIM:MTPH), a biotechnology company based in United Kingdom, saw significant share price volatility over the past couple of months on the AIM, rising to the highs ofRead More...